Climb Bio Operating Income Over Time
| CLYM Stock | 5.44 0.79 16.99% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Climb Bio Performance and Climb Bio Correlation. Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Climb Bio and related stocks such as Entera Bio, Spero Therapeutics, and Seres Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTX | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (5.4 M) | 11.3 M | (10.9 M) | (11.5 M) | (11.1 M) | (12.2 M) | (13 M) | (8.9 M) | (9.6 M) | (8.6 M) | (9.1 M) |
| SPRO | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (33.2 M) | (41.7 M) | (42.8 M) | (63.2 M) | (79.1 M) | (88 M) | (42.2 M) | 21.5 M | (73.4 M) | (66 M) | (69.3 M) |
| MCRB | (3 M) | (3 M) | (3 M) | (6.1 M) | (15.1 M) | (54.9 M) | (92.8 M) | (91.4 M) | (100.3 M) | (71.9 M) | (88.1 M) | (64.5 M) | (179.9 M) | (195.1 M) | (121.3 M) | (109.2 M) | (114.6 M) |
| ANIX | (1.7 M) | (4.1 M) | (7.9 M) | (5 M) | (944.8 K) | (4.5 M) | (6.1 M) | (13.7 M) | (11.9 M) | (10 M) | (13.1 M) | (13.9 M) | (11 M) | (13.8 M) | (11.7 M) | (10.5 M) | (10 M) |
| ABOS | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.9 M) | (19.6 M) | (45.2 M) | (61.1 M) | (114 M) | (102.6 M) | (97.5 M) |
| INO | (6.9 M) | (21.6 M) | (23.5 M) | (19.5 M) | (39.5 M) | (34.3 M) | (76.2 M) | (83.6 M) | (94.1 M) | (111.1 M) | (124.1 M) | (301.2 M) | (267.6 M) | (143.9 M) | (112.4 M) | (101.2 M) | (96.1 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (25 M) | (25.2 M) | (22.6 M) | (23.8 M) |
| TTRX | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (1.8 M) | (2.1 M) | (2.2 M) |
| VTGN | (4.8 K) | (9 M) | (6.8 M) | (5 M) | (6.8 M) | (17.9 M) | (10.2 M) | (14.2 M) | (24.6 M) | (20 M) | (17.9 M) | (47.8 M) | (59.3 M) | (33 M) | (56 M) | (50.4 M) | (47.9 M) |
| AGEN | (18.8 M) | (19.1 M) | (6.7 M) | (25 M) | (43.3 M) | (80.7 M) | (107.5 M) | (103.8 M) | (123.8 M) | (70.1 M) | (117.2 M) | 25.7 M | (179.4 M) | (159.5 M) | (120.5 M) | (108.4 M) | (103 M) |
Climb Bio and related stocks such as Entera Bio, Spero Therapeutics, and Seres Therapeutics Operating Income description
Operating Income is the amount of profit realized from Climb Bio operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Climb Bio is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Climb Bio | CLYM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 20 William Street, |
| Exchange | NASDAQ Exchange |
null 5.44
Check out Climb Bio Performance and Climb Bio Correlation. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Climb Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.